Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Phase III randomized, open-label study comparing GSK2118436 to Dacarbazine (DTIC) in previously untreated subjects with BRAF mutation positive advanced (Stage III) or metastatic (Stage IV) melanoma
dabrafenib
BRF113683
NCT01227889
Cancer
Phase 3
 
September 2013

Powered by ideaPoint, Inc.